Can I Take CoQ10 with Addyi (Flibanserin)?

What Is Flibanserin (Addyi) and How Does It Work?

Flibanserin is the only FDA-approved non-hormonal oral medication for hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts primarily as a 5-HT1A receptor agonist and a 5-HT2A receptor antagonist in the prefrontal cortex, shifting the balance between inhibitory serotonergic tone and excitatory dopaminergic/norepinephrine tone that governs sexual desire. The approved dose is 100 mg taken orally at bedtime to minimize dizziness and somnolence, which are its most common adverse effects.

FDA Approval and Indication

The FDA approved flibanserin in August 2015 under a Risk Evaluation and Mitigation Strategy (REMS) program because of the significant hypotension and syncope risk when co-administered with alcohol or with drugs that lower blood pressure. The REMS was later modified, but the boxed warning about hypotensive interactions has remained on the label. The FDA label specifically lists CYP3A4 inhibitors, CYP2C9 inhibitors, and alcohol as agents that can increase flibanserin exposure or potentiate hypotension. [1]

Pharmacokinetics: Why CYP Enzymes Matter Here

Flibanserin is metabolized predominantly by CYP3A4, with a minor contribution from CYP2C9. Its half-life is approximately 11 hours. Strong CYP3A4 inhibitors (such as fluconazole or ketoconazole) are contraindicated with Addyi because they raise flibanserin plasma concentrations by as much as 4.5-fold. Moderate inhibitors (such as fluoxetine or grapefruit juice) require caution. Understanding this metabolic pathway is the starting point for evaluating any new supplement, including CoQ10. [2]

What Is CoQ10 and Why Do Women Take It?

Coenzyme Q10 (CoQ10, also called ubiquinone in its oxidized form and ubiquinol in its reduced form) is a fat-soluble compound found in every cell's mitochondrial electron transport chain. It is biosynthesized endogenously but also consumed through diet, primarily from organ meats, fatty fish, and nuts. Women take CoQ10 for a range of reasons: as an antioxidant, for cardiovascular support, for migraine prevention, for fertility support during IVF cycles, and to offset statin-induced CoQ10 depletion. [3]

Doses Used in Clinical Practice

The therapeutic dose range studied in clinical trials spans 100 mg/day to 600 mg/day, though 200 to 300 mg/day is the most commonly used range for cardiovascular and blood pressure applications. Ubiquinol (the reduced form) is absorbed roughly 2- to 3-fold more efficiently than ubiquinone at equivalent doses in older adults. For women taking CoQ10 alongside lipid-lowering therapy, the American Heart Association has noted CoQ10 supplementation as a commonly used but still investigational strategy for statin-associated muscle symptoms. [4]

CoQ10 and Blood Pressure: What the Data Show

This is the point most relevant to the Addyi question. A meta-analysis of 12 clinical trials published in the Journal of Human Hypertension (2007, N=362 patients) found CoQ10 supplementation reduced systolic blood pressure by a mean of 11 mmHg and diastolic blood pressure by 7 mmHg compared to placebo. [5] The effect appears dose-dependent and more pronounced in people with pre-existing hypertension. For a woman whose resting blood pressure is already in the normal to low range, adding an antihypertensive supplement to an antihypertensive-prone drug like flibanserin creates a meaningful pharmacodynamic question even if no pharmacokinetic conflict exists.

Is There a Direct Drug-Supplement Interaction Between CoQ10 and Flibanserin?

The short answer is: no documented pharmacokinetic interaction has been published for this specific combination. CoQ10 is not a known inducer, inhibitor, or substrate of CYP3A4 or CYP2C9 in the peer-reviewed literature. No published case reports or clinical trials have examined the combination. The Natural Medicines database (a peer-reviewed interaction resource used by clinical pharmacists) does not list a direct interaction between CoQ10 and flibanserin as of the date of this article's review. [6]

Pharmacokinetic Verdict: Low Concern

Because CoQ10 does not meaningfully inhibit or induce the CYP enzymes that metabolize flibanserin, plasma concentrations of flibanserin are unlikely to be altered by CoQ10 co-administration. This is distinct from, say, combining Addyi with a CYP3A4 inhibitor such as clarithromycin, where the interaction is both documented and potentially dangerous. [2]

Pharmacodynamic Concern: Moderate, Context-Dependent

The real clinical concern is pharmacodynamic, not pharmacokinetic. Both flibanserin and CoQ10 can lower blood pressure, and their effects are at least theoretically additive. The Addyi prescribing information warns explicitly that women taking antihypertensive drugs at the same time as flibanserin are at higher risk of severe hypotension. [1] Whether CoQ10 at typical supplement doses produces clinically significant blood pressure reductions in normotensive premenopausal women (the primary Addyi population) is less certain than in hypertensive populations, but the 2007 meta-analysis shows the mechanism is real. [5]

The Alcohol Confound

One practical but underappreciated issue: many women taking Addyi are already counseled to avoid all alcohol. CoQ10 itself does not interact with alcohol in any dangerous way, but if a woman is managing the Addyi alcohol restriction carefully, adding any supplement that has cardiovascular activity is worth reviewing with her prescriber. The underlying risk profile of the drug, not just the supplement, sets the safety baseline.

Which Women Are at Greatest Risk from This Combination?

Not every woman taking Addyi faces the same pharmacodynamic risk from CoQ10. Risk stratification helps frame the conversation.

Women on Concurrent Antihypertensive Therapy

The Addyi label places women on antihypertensives in a high-risk category for hypotension. Adding CoQ10 at doses of 200 mg or more per day, given its demonstrated systolic BP reduction of up to 11 mmHg in hypertensive populations, could produce meaningful additive blood pressure lowering in this subgroup. A 2002 randomized controlled trial published in Hypertension found that 60 mg of CoQ10 twice daily produced significant reductions in systolic BP in isolated systolic hypertension, with effects appearing within 4 weeks. [7] Women in this category should be monitored with home blood pressure logs before and after starting CoQ10.

Women on Statins

Statins inhibit HMG-CoA reductase, which is the same mevalonate pathway that biosynthesizes CoQ10 endogenously. Atorvastatin 40 mg/day has been shown to reduce plasma CoQ10 concentrations by approximately 49% after 30 days in one prospective study. [8] Many premenopausal women are not yet on statins, but those who are may be taking CoQ10 specifically to replenish what the statin depletes. For these women, CoQ10 supplementation is a common clinical practice and the risk-benefit calculation typically favors supplementation, provided blood pressure is monitored.

Women with Baseline Low Blood Pressure

Premenopausal women as a demographic group often have lower baseline blood pressure than postmenopausal women or men. A woman whose resting systolic BP is 100 to 108 mmHg taking Addyi at bedtime and a CoQ10 supplement with dinner could theoretically experience orthostatic hypotension during nighttime bathroom visits. Syncope risk from Addyi is dose-timing dependent, which is why bedtime dosing is required.

A Clinical Decision Framework: CoQ10 + Addyi Risk Tiers

The following framework, developed by the HealthRX medical team, organizes patients into three tiers based on co-existing conditions and concurrent medications. This is not a validated scoring tool but a clinical thinking aid intended for use during prescriber review.

Tier 1 (Proceed with monitoring): Normotensive premenopausal women, no antihypertensives, no statins, CoQ10 dose at or below 200 mg/day, no regular alcohol use. Check seated and standing blood pressure at baseline and 4 weeks after starting CoQ10. Educate on syncope warning signs.

Tier 2 (Prescriber discussion required before starting CoQ10): Women on antihypertensive medication (any class), or women with baseline systolic BP below 110 mmHg, or women taking CoQ10 at doses above 300 mg/day. Home blood pressure monitoring twice daily for the first 4 weeks is reasonable. Consider morning CoQ10 dosing to maximize the time gap from bedtime Addyi.

Tier 3 (Formal clinical review before combining): Women on both an antihypertensive and a statin, or women who have previously experienced dizziness or near-syncope on Addyi alone, or women taking strong vasodilators (such as nitrates). In this tier, the pharmacodynamic additive risk is highest, and the prescriber may wish to formally re-evaluate whether continuing Addyi at 100 mg is appropriate, or whether dose reduction to 50 mg (off-label) is safer while CoQ10 is added.

Dose Timing: Does It Help to Separate Addyi and CoQ10?

Separating the peak plasma concentrations of the two agents is a practical harm-reduction strategy even when a formal interaction has not been proven. Flibanserin reaches peak plasma concentration (Tmax) approximately 45 minutes to 2 hours after an oral dose and has a half-life of about 11 hours. [2] CoQ10 is fat-soluble and reaches Tmax approximately 6 hours after a dose taken with a fatty meal.

Taking Addyi at bedtime (for example, 10 pm) and CoQ10 with breakfast or lunch (7 am to 12 pm) means the two agents peak at very different times, reducing the window where both are at maximum pharmacological effect simultaneously. This is not a pharmacokinetic solution (the agents do not interact pharmacokinetically), but it is a pharmacodynamic spacing strategy that mirrors how prescribers often time antihypertensives to avoid simultaneous trough blood pressure effects.

The Endocrine Society's 2019 guidelines on HSDD management note that the timing and adherence context around flibanserin dosing is clinically significant because of the drug's narrow therapeutic window relative to its adverse effect profile. [9] A timed CoQ10 dose fits naturally into this same careful-timing framework.

What CoQ10 Does Not Do: Clarifying Common Misconceptions

Several online sources suggest CoQ10 could reduce the effectiveness of Addyi by "interfering with neurotransmitter balance." This claim has no mechanistic basis. CoQ10 operates in the mitochondrial electron transport chain and as a lipid-phase antioxidant; it does not bind serotonin receptors, dopamine receptors, or norepinephrine transporters at physiological plasma concentrations. The 5-HT1A and 5-HT2A receptor activity that underpins flibanserin's mechanism is not mediated by the CoQ10 redox pathway. [3]

A second misconception is that CoQ10 is always neutral for women with HSDD. Some observational data suggest mitochondrial function and oxidative stress play a role in the neurobiological underpinnings of desire disorders, and a 2021 review in Nutrients examined antioxidant pathways in female sexual dysfunction broadly. [10] But this is mechanistic speculation, not clinical evidence that CoQ10 improves HSDD outcomes. Women should not substitute CoQ10 for proven HSDD therapy.

Monitoring Parameters If You Decide to Combine Both

If a woman and her prescriber decide to proceed with CoQ10 while on Addyi, a simple monitoring plan reduces risk meaningfully.

Blood Pressure Checks

Check seated and standing blood pressure at baseline (before starting CoQ10), at 2 weeks, and at 4 weeks. A drop in standing systolic BP of more than 20 mmHg compared to seated, or any standing systolic below 90 mmHg, warrants stopping CoQ10 and reassessing.

Symptom Diary

Track dizziness, lightheadedness, and near-fainting episodes, particularly in the 1 to 3 hours after bedtime and upon standing from lying. Addyi's hypotensive effects are most pronounced in the first 2 to 4 hours after dosing due to its pharmacokinetic profile. If CoQ10 is taken with dinner and Addyi at bedtime, the overlap window is the late evening and early morning.

Drug Interaction App or Pharmacist Review

Clinical pharmacists use tools such as Lexicomp, Micromedex, and Natural Medicines to screen for interactions. As of 2025, the flibanserin-CoQ10 pair is not flagged as a major interaction in standard databases. Confirming this with a pharmacist when filling the prescription costs nothing and provides an additional safety checkpoint.

What Guideline Documents Say About Addyi Co-administration

The FDA prescribing information for flibanserin (Sprout Pharmaceuticals, label revised 2021) states: "Coadministration of flibanserin with alcohol or with drugs that lower blood pressure may increase the risk of hypotension and syncope." [1] It does not name CoQ10 specifically, but the pharmacodynamic category it describes, drugs or substances that lower blood pressure, is relevant.

The North American Menopause Society (NAMS) 2022 position statement on female sexual dysfunction states that flibanserin has "modest efficacy" for HSDD with a number-needed-to-treat of approximately 8 to 15 for one additional satisfying sexual event per month, and that "careful attention to drug interactions and patient selection is essential given the drug's adverse effect profile." [11]

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 213 on female sexual dysfunction acknowledges flibanserin as a treatment option while noting that counseling on drug-drug and drug-alcohol interactions is a requirement before prescribing. [12]

Clinical Bottom Line

CoQ10 does not inhibit CYP3A4 or CYP2C9 and does not raise flibanserin plasma levels. The concern is pharmacodynamic: both agents reduce blood pressure, and the Addyi label already carries a boxed warning about additive hypotension. For normotensive women on no antihypertensives, 100 to 200 mg/day of CoQ10 taken in the morning while Addyi is taken at bedtime represents a low-risk approach, provided blood pressure is checked at 2 and 4 weeks. Women on antihypertensives, statins, or who have baseline systolic BP below 110 mmHg need a prescriber conversation before combining. No clinical trial has studied this exact combination. Until one does, monitoring blood pressure and dizziness symptoms is the most evidence-informed safeguard available.